Gyre Therapeutics outlined a strategy to fund targeted protein degrader and degrader antibody-conjugate programs using China commercial cash flows.
FY26 ETUARY total revenue guidance set at $100.5 million-$111 million from its market-leading pirfenidone brand in China for idiopathic pulmonary fibrosis.
Pipeline update and development timeline
Hydronidone (F351) NDA filing accepted by China’s NMPA in May 2026; potential launch in early 2027 for CHB-induced liver fibrosis.
Two degrader candidates targeted for IND submission in Q1 2027, with Phase 1 starts planned in 2027 in the U.S. or China.
Pan-TRK degrader CG00141G completed Phase 1 in healthy volunteers; Phase 2 planning for cancer-induced bone pain in the U.S. or China.
GYRE•
